NCT04876781View on ClinicalTrials.gov

Korean Post-marketing Surveillance for Xeljanz XR

RecruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

December 6, 2026

Study Completion Date

December 6, 2026

Conditions

Active Moderate to Severe Rheumatoid ArthritisActive Ankylosing SpondylitisActive Psoriatic Arthritis

Interventions

DRUG

Tofacitinib XR

Tofacitinib XR 11mg

Trial Locations (1)

Unknown

RECRUITING

Pfizer, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT04876781 - Korean Post-marketing Surveillance for Xeljanz XR | Biotech Hunter | Biotech Hunter